A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK1001 and Pembrolizumab Versus Placebo and Pembrolizumab as First-Line Therapy in Participants With Advanced Melanoma (TeLuRide-006)

Protocol Number: 202504194
Principal Investigator: Ansstas, George
Cancer Types: Melanoma &amp; Skin

Learn more about this study at: clinicaltrials.gov

For more information on this trial, contact us here:

Brief Summary

The study is for patients with advanced melanoma who are eligible for standard therapy with Pembrolizumab.

Drug: EIK1001, Drug: Pembrolizumab (KEYTRUDA® )